Gubra AS GUBRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- DKK 484.00
- Day Range
- DKK 474.00–504.00
- 52-Week Range
- DKK 90.09–754.00
- Bid/Ask
- DKK 487.00 / DKK 491.00
- Market Cap
- DKK 7.96 Bil
- Volume/Avg
- 22,194 / 66,082
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 35.87
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.03%
Company Profile
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has three segments: Pre-clinical contract research (CRO), which derives maximum revenue; Discovery & Partnerships (D&P) Segment; and Gubra Green Segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 235
- Website
- https://www.gubra.dk
Comparables
Valuation
|
Metric
|
GUBRA
|
02509
|
BAVA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 13.54 |
Price/Book Value | 17.02 | 32.16 | 1.65 |
Price/Sales | 35.87 | 98.68 | 2.82 |
Price/Cash Flow | — | — | 8.40 |
Price/Earnings
GUBRA
02509
BAVA
Financial Strength
|
Metric
|
GUBRA
|
02509
|
BAVA
|
|---|---|---|---|
Quick Ratio | 7.16 | 1.70 | 0.91 |
Current Ratio | 7.24 | 1.86 | 1.48 |
Interest Coverage | −11.85 | −18.42 | 5.69 |
Quick Ratio
GUBRA
02509
BAVA
Profitability
|
Metric
|
GUBRA
|
02509
|
BAVA
|
|---|---|---|---|
Return on Assets (Normalized) | −7.51% | −47.40% | 9.32% |
Return on Equity (Normalized) | −9.63% | −341.08% | 13.26% |
Return on Invested Capital (Normalized) | −9.11% | −56.34% | 13.68% |
Return on Assets
GUBRA
02509
BAVA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Pxrddkwhtm | Bdtp | $526.2 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Npqxzvrp | Qxjjxnn | $115.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vmzcjkj | Bjhph | $109.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xsbxzhmw | Xzdkphz | $34.2 Bil | |||
| argenx SE ADR
ARGX
| Tndldhs | Rgr | $31.5 Bil | |||
| BioNTech SE ADR
BNTX
| Pfvhvlhg | Crqz | $28.9 Bil | |||
| Moderna Inc
MRNA
| Pfdsjnljk | Jhg | $22.6 Bil | |||
| United Therapeutics Corp
UTHR
| Zdxvpqcwf | Bxqbt | $15.6 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Gsvkkcdhj | Qjyfdst | $13.1 Bil | |||
| Incyte Corp
INCY
| Kxpxgqp | Cbyrwz | $12.7 Bil |
United States